Rigel Pharmaceuticals reported $-13492000 in Net Income for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Net Income Change
Agenus AGEN:US $ -46.43M 1.89M
Amgen AMGN:US $ 1317M 159M
Anika Therapeutics ANIK:US $ -2.84M 0.09M
Applied Genetic Technologies AGTC:US $ -14.29M 4.85M
Arrowhead Research ARWR:US $ -72046000 116.41M
AstraZeneca AZN:LN 360M 26M
Astrazeneca AZN:US $ 360M 26M
Biomarin Pharmaceutical BMRN:US $ 27.66M 93.13M
Bristol Myers Squibb BMY:US $ 1421M 143M
Celldex Therapeutics CLDX:US $ -36M 12.95M
Chemocentryx CCXI:US $ -31.65M 6.96M
Daiichi Sankyo 4568:JP Y 18852M 46197M
Eli Lilly And LLY:US $ 952.5M 950.4M
Halozyme Therapeutics HALO:US $ 22.68M 37.42M
Immunogen IMGN:US $ -62.02M 37.88M
Karyopharm Therapeutics KPTI:US $ -49062000 7.66M
Macrogenics MGNX:US $ -41.3M 25.14M
Neurocrine Biosciences NBIX:US $ -16.9M 30.8M
Pfizer PFE:US $ 9905M 2042M
Regeneron Pharmaceuticals REGN:US $ 852.1M 121.4M
Rigel Pharmaceuticals RIGL:US $ -13.49M 13.95M
Sangamo Biosciences SGMO:US $ -43.17M 0.8M
Ultragenyx Pharmaceutical RARE:US $ -158.16M 5.84M
Veracyte VCYT:US $ -9.53M 4.93M